Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Christopher Gibson, CEO of Recursion Pharmaceuticals, reports the withholding of shares to cover tax obligations and ongoing vesting of stock options.
Summary
- On May 15, 2024, Christopher Gibson, the CEO of Recursion Pharmaceuticals, reported changes in his beneficial ownership of the company's stock.
- 26,082 Class A Common Stock shares were withheld by the issuer to satisfy tax obligations related to the net settlement of restricted stock units at a price of $10.01.
- Following the transaction, Gibson directly owns 808,738 shares of Class A Common Stock.
- Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
- He holds options to purchase Class A Common Stock at various exercise prices and vesting schedules, including options for 813,600 shares at $8.55, 312,500 shares at $2.48, 399,002 shares at $11.4, and 666,898 shares at $10.09.
- Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating neutral sentiment. It reflects standard compensation practices and tax obligations.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The filing provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 02/04/2022 | Date of stock option grant with an exercise price of $11.4 and an expiration date of 02/04/2032. |
| 03/01/2023 | Start date for vesting of one stock option grant, with one forty-eighth of the shares vesting monthly thereafter. |
| 03/01/2024 | Start date for vesting of another stock option grant, with one forty-eighth of the shares vesting monthly thereafter. |
| 05/15/2024 | Date of the reported transaction involving the withholding of shares for tax obligations. |
| 05/17/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.